Henry Schein HSIC
Healthcare · Medical - Distribution · Synthos Deep Dive · 2026-07-03
The Overview
Henry Schein is the "Costco-plus-Amazon" of the dentist's office: it's the middleman that ships dental and medical supplies, equipment, and practice-management software to hundreds of thousands of dentists and doctors. It is a steady, boring, recession-resistant business — people keep going to the dentist even in bad times — but it is not a fast grower. Sales creep up about 3–5% a year, and the company makes only about 3 cents of profit on every dollar of sales, so there is not much cushion if something goes wrong.
Is the stock cheap or expensive? It's roughly fairly priced — trading right around what we and Wall Street think it's worth. Our verdict is Watch: a fine business, but with the price already up near its 12-month high and only a couple percent of upside, there's no bargain here and no reason to rush in.
Here's what our three scores mean in everyday terms:
- Downside Risk 5/10 (middle of the road). The stock is calm and the demand is dependable, but the company carries a fair amount of debt and razor-thin margins, so a bad quarter hurts.
- Growth Quality 4/10 (below average). Growth is slow and a lot of the per-share earnings growth comes from the company buying back its own shares, not from the business booming.
- Exponential Potential 3/10 (low). This is a mature, slow-and-steady company. Do not expect it to double quickly.
The one big worry: because profit margins are so thin, even a small drop in dental or medical demand can knock earnings down a lot more than you'd expect.
Putting a number on it: our fair-value estimate is $88 against a current price of $89.52 — a premium price for a business we still like.
Our summary metrics
Low beta (0.82) & defensive demand, but net-debt/EBITDA 3.6× and thin 3% net margins leave little error room.
~3-5% organic sales, high-single-digit non-GAAP EPS growth via buybacks & margin self-help — steady, not high-quality compounding.
Mature low-growth distributor; ~$9.8B cap vs a large but slow TAM; no acceleration — this is not an exponential.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Mature low-growth distributor; ~$9.8B cap vs a large but slow TAM; no acceleration — this is not an exponential.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $87.43 (high $100 / low $64; 15 Buy · 15 Hold · 3 Sell) — context, not our anchor |
| Valuation | 26× trailing GAAP EPS · ~16× FY26E non-GAAP · ~15× FY27E · EV/S 1.0× · EV/EBITDA 13.4× |
| Technicals | Uptrend but stretched — $86.43 at the 52-wk high, RSI 71 (overbought), +16% 12-mo but lagging SPY +21% |
| Conviction | Low — 0 expert voices in the Synthos KB; call rests entirely on fundamentals & quant |
| Position sizing | Small/defensive only, ~1–2% if held; not a flagship-conviction name |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for HSIC — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $89.52, 3% above the 50-day average ($87), 14% above the 200-day average ($79) — an uptrend. 1% below the 52-week high of $91, 44% above the 52-week low of $62.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $89.52 is currently inside the band (band $87–$91).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 58.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.13, negative momentum.
Relative performance vs S&P 500 & its sector (XLV (sector)), set to 100 a year ago
Solid = HSIC · dashed = S&P 500 · dotted = XLV (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Henry Schein, Inc. (NASDAQ: HSIC) is a ~90-year-old (founded 1932) global distributor of healthcare products and services to office-based dental and medical practitioners — the largest such distributor in the world, serving more than 1 million customers across 34 countries with ~25,000 employees. Fiscal year ends late December.
The business runs in two segments:
- Health Care Distribution — the core: dental consumables (infection control, impression materials, composites, anesthetics), dental equipment (chairs, handpieces, X-ray/digital imaging), plus medical supplies, pharmaceuticals, vaccines, and PPE. Low-margin, high-volume, sticky.
- Technology & Value-Added Services — practice-management software for dental and medical offices, plus financial services, e-services, and consulting. Smaller but higher-margin and faster-growing (Global Technology sales +7.0% in Q1'26; Value-Added Services +10.6%).
Revenue mix (from filings & the Q1'26 release):
- By type: the vast majority is Health Care Distribution; Technology & Value-Added Services is the minority but the growth/margin engine. (FMP's product segmentation only carries stale 2018 splits — Healthcare Distribution ~$12.7B vs Technology ~$0.5B — so treat the exact split as directional; the Q1'26 release growth rates above are the fresh read.)
- By geography: US-centric. FMP's most recent geo tag shows US ~$9.1B of the $13.18B FY25 total (~69% US), with the balance international (Europe-weighted). US concentration is a stability strength but a US-dental-demand-cyclicality exposure.
2. The expert thesis — (no expert coverage)
There is no expert coverage of HSIC in the Synthos knowledge base. total_claims = 0; there are zero net-bullish and zero cautionary voices. No claim_id values exist to cite.
This is stated plainly because honesty comes first: the verdict here is entirely fundamentals- and quant-driven, built from the FMP financials, analyst estimates, management's own guidance, and the technical/valuation picture below. It carries Low conviction by construction — not because the business is bad, but because no tracked expert in our panel has expressed a signed view on it. Readers should weight this note accordingly and lean on the primary data, not on a crowd of analysts we can point to.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 5 · Moderate | Beta 0.82 and non-discretionary demand cushion the downside, but net-debt/EBITDA 3.6× and a ~3% net margin mean a small sales miss becomes a big EPS miss. Not richly valued (16× fwd non-GAAP), which caps de-rating risk. |
| Growth Quality | 4 · Below-average | Organic sales only ~2.5% (Q1'26 internal growth); non-GAAP EPS grows high-single-digit largely via buybacks and margin self-help, not volume. ROIC ~6%, ROE ~12% — adequate, not elite. Sticky but low-quality compounding. |
| Exponential Potential | 3 · Low | Mature category leader; no acceleration (revenue growth is flat-to-decelerating), TAM large but slow. A ~$9.8B cap in a low-growth distribution market does not multibag. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores above summarize them. Note: valuation multiples below are on non-GAAP / adjusted EPS, consistent with management guidance and the FMP consensus estimates, which run ~$2 above GAAP EPS due to intangible amortization and restructuring add-backs.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Value-creation initiatives ($200M+ operating-income uplift) land in full; margins expand; sales grow ~5%+; dental equipment cycle recovers. FY27E non-GAAP EPS beats to ~$6.2; multiple re-rates to ~17.5×. | ~$108 (+25%) |
| Base (our anchor) | Guidance roughly holds — FY26E non-GAAP EPS ~$5.35, FY27E ~$5.9; steady ~3–5% sales, high-single-digit EPS growth; multiple holds ~15.5× FY27E. | ~$88 (+2%) |
| Bear | Dental/medical volume soft patch; margin initiatives slip; FX headwind; FY27E EPS misses to ~$5.2; multiple de-rates to ~12×. | ~$62 (−28%) |
Synthos fair value = the base case, ~$88 (+2%), with the full $62–$108 span as the honest range. This anchor sits essentially on top of the Street's $87.43 consensus — a rare case where our independent model and the sell-side converge, which itself is a signal that the name is efficiently priced with little edge either way. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). HSIC is neither an exponential nor even a high-quality compounder — it is a mature, low-growth defensive distributor:
- Forward growth: revenue CAGR FY25→FY29E is only ~3.8% ($13.18B → $15.33B). Non-GAAP EPS CAGR is faster (~high-single-digit) but that gap is buyback-driven — diluted shares fell from ~127M (FY24) to ~116M (Q1'26), i.e. the company is shrinking the share count ~5–6%/yr.
- Acceleration (2nd derivative) is flat-to-negative: revenue growth was +4.0% (FY25) and consensus has it decelerating to ~+4.3% (FY26E) then ~+3.9%/+3.7% (FY27–28E). There is no inflection; this is a GDP-plus grinder.
- Room to run: the dental/medical distribution TAM is large but structurally slow and highly penetrated; Schein already leads it. A ~$9.8B cap here does not become a $30–50B company on organic distribution — the math doesn't support a multibagger.
- Reinvestment runway: capital goes to bolt-on M&A (~$276M FY25) and buybacks, not to a high-return organic reinvestment flywheel. Fine capital return; not an exponential engine.
Exponential Potential: Low (3/10). Own it, if at all, for defensive stability and share-count shrinkage — never for a fast multibagger. This honest framing is why HSIC sits in the Watch bucket, not any conviction sleeve.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $13.18B, +4.0% (FY24 $12.67B, +2.7% on FY23 $12.34B). Slow, steady, non-cyclical-ish top line.
- Quarterly trajectory: Q1'25 $3.17B → Q2 $3.24B → Q3 $3.34B → Q4 $3.44B → Q1'26 $3.37B (+6.3% YoY, but only +2.5% internal/organic — the rest was FX +3.1% and M&A +0.7%).
- Margins (the key vulnerability): gross 29.7% TTM, EBITDA margin 7.5%, operating ~5.6%, and net just ~3.0% TTM. Thin margins mean high operating leverage to the downside — a small revenue disappointment amplifies into EPS.
- Earnings: GAAP net income $398M FY25 (flat vs $398M FY24), GAAP diluted EPS $3.27 (up from $3.05 on a lower share count). Note the large GAAP-vs-non-GAAP gap: Q1'26 GAAP diluted EPS $0.92 vs non-GAAP $1.32 — the ~$0.40/qtr wedge is intangible amortization, restructuring, and value-creation implementation costs. Consensus and guidance are quoted on the non-GAAP number.
- Cash flow: operating CF $712M FY25, capex ~−$139M, FCF ~$573M (FCF yield ~4.4% on EV). Solid cash conversion for a distributor; funds the buyback.
- Balance sheet: total debt $3.69B, net debt $3.53B, net-debt/EBITDA ~3.6× — the highest-risk line on the page. Serviceable (interest coverage ~4.9×) but leaves less room than a fortress balance sheet; the FMP debt-to-equity score is a 1/5 (weakest metric in the letter rating).
6. Valuation — priced in or room?
HSIC is fairly valued, not cheap and not expensive. The headline 26× trailing figure is on GAAP EPS ($3.27) and is misleading — on the non-GAAP basis that management guides and the Street models, the multiple is ~16× FY26E ($5.35) → ~15× FY27E ($5.92) → ~13× FY29E ($6.74). EV/EBITDA is 13.4× and EV/sales just 1.0× (appropriate for a thin-margin distributor). A PEG on high-single-digit EPS growth lands near ~1.8–2.4× — full but not egregious for a defensive name.
The problem isn't the multiple, it's the lack of a gap between price and value: our base-case fair value (~$88) and the Street consensus ($87.43) both sit within ~2% of the current $86.43 price. There is no obvious mispricing to exploit. Street targets (context): consensus $87.43, high $100, low $64 — a wide dispersion that reflects genuine uncertainty about whether the margin/value-creation initiatives deliver. Not a value buy; a fairly-priced defensive hold.
7. Technicals (from the tech block)
- Trend: up. $86.43 sits above the 50-DMA ($76.87) and 200-DMA ($74.33), and the 50 is above the 200 (golden-cross posture). MACD +2.39 (positive).
- Location: at the 52-week high (0.0% off) and +39% off the 52-week low ($62.03), with a shallow max drawdown of only ~−6% from peak — a name grinding to new highs with low volatility.
- Momentum: RSI(14) 71 — overbought (>70). This is a stretched-entry warning: buying right at the high after a run is the worst risk/reward point.
- Relative strength (the tell): HSIC +16.0% 12-mo vs SPY +20.6% and QQQ +30.3% — it is lagging both the market and (especially) growth over 12 months, though it has outperformed SPY over the last 3 months (+18.3% vs +13.7%) on a recent catch-up. A defensive laggard having a moment, not a secular leader.
- Read: technicals are constructive but overbought at the high — no urgency to chase; a pullback toward the rising 50-DMA (~$77) would be a far better risk-adjusted entry for anyone who wants the name.
8. Moat & competitive position
HSIC's moat is scale and stickiness, not pricing power: it is the largest dental/medical distributor, with a centralized automated distribution network, 300,000+ SKUs, embedded practice-management software (high switching costs once a dental office runs on Schein's software and ordering system), and decades of practitioner relationships. That produces durable, recurring, low-cyclicality demand — the genuine strength here. But it is a low-margin intermediary in a slow-growth category, structurally exposed to (a) manufacturer direct-to-practice disintermediation, (b) e-commerce price transparency, and (c) group-purchasing/DSO consolidation squeezing distributor margins. The moat protects the volume, not the margin.
Peer set (FMP, market cap): DaVita $15.1B, Molina Healthcare $12.0B, Globus Medical $10.8B, Masimo $9.4B, Halozyme $9.4B, Bio-Rad $8.0B, AptarGroup $8.1B, Avantor $7.0B, Grifols $6.1B. This is an FMP "similar-size healthcare" basket rather than true distribution comps (Patterson and the med-distribution majors like McKesson/Cardinal/Cencora are the real peers) — read it as a size cohort, not a valuation anchor.
9. Management, capital allocation & guidance
- Capital allocation: shareholder-return-heavy. FY25 bought back $850M of stock (and repurchased ~1.6M shares at ~$77.64 for $125M in Q1'26, with $655M authorization remaining); no dividend. Bolt-on M&A ~$276M FY25 (e.g. the S.I.N. dental-implant distributor stake). The buyback is the main per-share-EPS lever given slow organic growth.
- Leadership: new-ish CEO Fred Lowery (the Q1'26 release is in his voice, describing "immersing myself in the business"), following a period of activist/shareholder-advisory involvement. FMP lists Andrea Albertini as CEO in the profile — a data lag; the earnings release confirms Fred Lowery as CEO. A leadership transition adds execution uncertainty to the value-creation plan.
- Insider activity: routine — a director equity award (2026-06-15), a new officer's Form 3 (SVP/General Counsel, 2026-05-28), and small charitable gifts by former director Stanley Bergman. No cluster of alarming discretionary open-market selling in the sampled window.
- Management's own guidance (half-weighted — their self-interested words): in the 2026-05-05 Q1'26 earnings release (SEC 8-K, Item 2.02), management reaffirmed FY2026 guidance: non-GAAP diluted EPS $5.23–$5.37, total sales growth ~3–5% over 2025, and Adjusted EBITDA growth mid-single-digit. CEO Lowery framed a multi-year goal of >$200M of annual operating-income improvement (with a $125M run-rate by end-2026) from value-creation initiatives, and guided to "high-single digit to low-double digit earnings growth in the coming years." This is management's own book (half-weight): it is a reaffirmation, not a raise, and the EPS growth is heavily buyback- and self-help-dependent.
10. Catalysts & what to watch
- Next earnings: 2026-08-04 (Q2'26; Street EPS $1.22, revenue ~$3.38B). The key lines: internal/organic sales growth (was only +2.5% in Q1) and gross-margin expansion from the value-creation initiatives.
- Value-creation execution: evidence the $125M run-rate by year-end 2026 operating-income improvement is materializing — the swing factor for the bull case.
- Dental equipment cycle: equipment sales (+8.6% in Q1'26) are the discretionary, higher-margin end — a leading indicator of practitioner confidence.
- Buyback pace: continued share-count reduction ($655M authorized) supports EPS even if revenue is flat.
- FX: ~3% of Q1 growth was currency — a swing that can flatter or hurt reported numbers.
Thesis tripwires (what would change the call): two consecutive quarters of negative organic sales growth; gross margin failing to expand despite the initiatives; net-debt/EBITDA rising above ~4×; or a guidance cut (vs the current reaffirmation). Conversely, a credible re-rate would need organic growth to break above ~5% with visible margin gains.
11. Key risks
- Thin-margin operating leverage (structural): a ~3% net margin means a small revenue miss (soft dental/medical volumes) produces an outsized EPS miss. This is the single biggest risk.
- Leverage: net-debt/EBITDA ~3.6× is the highest-risk metric; limits flexibility and amplifies any EBITDA shortfall.
- Disintermediation / margin compression: manufacturer-direct, e-commerce price transparency, and DSO/GPO consolidation all pressure distributor economics over time.
- Execution / leadership transition: the value-creation plan and a newer CEO add delivery risk to guidance that is already reaffirmed-not-raised.
- Low conviction / no expert coverage: unlike our flagship names, no tracked expert has a signed view here — the call rests solely on data, so unknown-unknowns are less well hedged.
- No margin of safety: at ~+2% to fair value and RSI 71 at the 52-week high, the entry point offers no cushion.
12. Verdict, position sizing & monitoring
Watch. Henry Schein is a genuinely defensive, sticky, well-run distributor — low beta, non-discretionary demand, strong cash conversion, and a disciplined buyback shrinking the share count ~5–6%/yr. But it is a low-growth (~3–5% organic), thin-margin (~3% net), moderately levered (3.6× net debt/EBITDA) business trading right at fair value (~+2% upside, base case ~$88 vs $86.43) and at its 52-week high with an overbought RSI of 71. There is no expert conviction behind it (0 KB claims) and no valuation edge to exploit. That combination is the textbook definition of a Watch, not a buy.
- Sizing: if owned at all, a small ~1–2% defensive sleeve position — and better initiated on a pullback toward the ~$77 50-DMA than at the high. This is not a conviction/flagship weight.
- Monitoring: re-underwrite on the §10 tripwires — the whole upside case depends on the value-creation margin initiatives landing; formal re-score each earnings print. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $86.43.
- Single biggest risk: thin-margin operating leverage — on a 3% net margin with 3.6× leverage, a modest volume soft patch turns a small revenue miss into a large EPS miss.
What would move us to Buy — Tactical: a pullback to the low-$70s (restoring a double-digit margin of safety to fair value) or clear evidence the >$200M value-creation program is expanding gross margin and lifting organic growth toward 5%+.
Provenance & disclosures
- Traceability: 0 KB claims — there is no expert coverage of HSIC in the Synthos knowledge base, so no
claim_idvalues are cited. Fabricated conviction is structurally impossible (claim-ID reconciliation); this note is explicitly fundamentals- and quant-driven and labeled Low conviction. - Data as-of: fundamentals 2026-03-28 (Q1'26) · estimates & prices 2026-07-02/03 · management guidance from the 2026-05-05 SEC 8-K (Item 2.02) earnings release. Forward figures are analyst consensus (FMP) or management guidance, labeled as estimates; consensus/guidance EPS is non-GAAP (~$2 above GAAP).
- Management caveat: management's reaffirmed FY26 guidance is management's own self-interested book, half-weighted by design.
- Data note: FMP lists the CEO as "Andrea Albertini" (profile lag) while the Q1'26 release confirms Fred Lowery; product-segment splits in FMP are stale (2018). Peer basket is a size cohort, not true distribution comps.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").